Evidence map›Paper›PMID 40844066›Full record

ArticleIndian journal of pharmacology2025

A case series of vildagliptin-associated bullous pemphigoid - Rare side effect.

Mohit Kumar Shahi, J V Ashwin, Astha Singh, Suvrat Gupta, K Surya

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Indian journal of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mohit Kumar ShahiDepartment of GMH, King George Medical University, Lucknow, Uttar Pradesh, India.
J V AshwinDepartment of GMH, King George Medical University, Lucknow, Uttar Pradesh, India.
Astha SinghDepartment of Psychiatry, Hind Institute of Medical Sciences, Barabanki, Uttar Pradesh, India.
Suvrat GuptaDepartment of PMR, Hind Institute of Medical Sciences, Barabanki, Uttar Pradesh, India.
K SuryaDepartment of Pharmacology, King George Medical University, Lucknow, Uttar Pradesh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vildagliptin, among the most commonly used, OHA, belongs to group dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus, has recently been associated with bullous pemphigoid, characterized by fluid-filled blisters and erosions on the skin and mucous membranes. We report the series of three cases of bullous pemphigoid in patients of diabetes, who developed bullous pemphigoid after vildagliptin use.

Indexed as

AdamantaneDipeptidyl-Peptidase IV InhibitorsNitrilesPemphigoid, BullousPyrrolidinesDiabetes Mellitus, Type 2HumansVildagliptinAdamantaneDipeptidyl-Peptidase IV InhibitorsNitrilesPyrrolidinesVildagliptinBullous pemphigoiddiabetesdipeptidyl peptidase-4vildagliptin

Identifiers

PMID40844066
PMCPMC12419561

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.